Effects of recombinant human growth hormone on enterocutaneous fistula patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

232

HTML

2144

Figures (1-1)

166

Tables (1-3)

195

Sum=2737

Nov 28, 2008 (publication date) through Nov 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 28, 2008; 14(44): 6858-6862
Published online Nov 28, 2008. doi: 10.3748/wjg.14.6858

Table 2 Changes of intestinal mucosal villus height, PCNA and nitrogen excretion before and after treatment with rhGH

	The days when treated with rhGH
	0	4	7
Villus height (μm)	210.94 ± 49.16	500.54 ± 53.79^b	459.03 ± 88.98^b
PCNA labelling index (%)	12.92 ± 4.20	24.93 ± 3.41^b	30.46 ± 5.24^b
Nitrogen excretion (g/d)	7.25 ± 3.92	4.64 ± 1.95	3.40 ± 1.65^a

All values are expressed as mean ± SD.

^aP < 0.05,

^bP < 0.01 vs day 0.

Citation: Gu GS, Ren JA, Li N, Li JS. Effects of recombinant human growth hormone on enterocutaneous fistula patients. World J Gastroenterol 2008; 14(44): 6858-6862
URL: https://www.wjgnet.com/1007-9327/full/v14/i44/6858.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6858